Future studies are warranted to determine how USP13 reprograms lineage plasticity in USP13-amplified lung cancers and whether targeting USP13 can overcome therapeutic-resistant LUSC-transformed lung tumors. This evidence concerns the gene USP13 and lung carcinoma.